Tandem Diabetes Care Inc Asset Resilience Ratio
Tandem Diabetes Care Inc asset resilience ratio. Tandem Diabetes Care Inc (TNDM) has an Asset Resilience Ratio of 34.06% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See TNDM defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Tandem Diabetes Care Inc (2011–2025)
Asset resilience ratio of Tandem Diabetes Care Inc from 2011 to 2025. This chart shows how Tandem Diabetes Care Inc's Asset Resilience Ratio has changed over time. Read TNDM total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Tandem Diabetes Care Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Tandem Diabetes Care Inc balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $393.18 Million | 34.06% |
| Total Liquid Assets | $393.18 Million | 34.06% |
Asset Resilience Insights
- Very High Liquidity: Tandem Diabetes Care Inc maintains exceptional liquid asset reserves at 34.06% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Tandem Diabetes Care Inc Industry Peers by Asset Resilience Ratio
Compare Tandem Diabetes Care Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Shanghai Sanyou Medical Co Ltd
SHG:688085 |
Medical Devices | 7.69% |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607 |
Medical Devices | 16.21% |
|
Cleo Diagnostics Ltd
AU:COV |
Medical Devices | 94.64% |
|
Memphasys Ltd
AU:MEM |
Medical Devices | 0.00% |
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
Tandem Diabetes Care Inc Asset Resilience Ratio by Year (2011–2025)
Tandem Diabetes Care Inc asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for Tandem Diabetes Care Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 22.93% | $202.03 Million | $881.11 Million | -15.21pp |
| 2024-12-31 | 38.14% | $369.10 Million | $967.66 Million | -4.79pp |
| 2023-12-31 | 42.94% | $409.04 Million | $952.66 Million | +0.73pp |
| 2022-12-31 | 42.21% | $444.38 Million | $1.05 Billion | -18.84pp |
| 2021-12-31 | 61.05% | $552.63 Million | $905.14 Million | +6.57pp |
| 2020-12-31 | 54.48% | $390.32 Million | $716.41 Million | +16.07pp |
| 2019-12-31 | 38.42% | $125.28 Million | $326.11 Million | -3.85pp |
| 2018-12-31 | 42.27% | $87.20 Million | $206.29 Million | +41.77pp |
| 2017-12-31 | 0.50% | $479.00K | $95.35 Million | -7.38pp |
| 2016-12-31 | 7.88% | $8.86 Million | $112.39 Million | -14.51pp |
| 2015-12-31 | 22.39% | $28.02 Million | $125.12 Million | -11.52pp |
| 2014-12-31 | 33.91% | $36.11 Million | $106.46 Million | +30.77pp |
| 2013-12-31 | 3.14% | $5.10 Million | $162.22 Million | +3.02pp |
| 2012-12-31 | 0.13% | $50.00K | $39.82 Million | -0.23pp |
| 2011-12-31 | 0.36% | $50.00K | $13.98 Million | -- |
About Tandem Diabetes Care Inc
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and … Read more